{"analyses":[{"ciLowerLimit":"-27.42","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"-6.23","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0026","pValueComment":"Ranked 5 of 7 in the fixed sequence for type I error control. P-value is nominal as the hierarchical testing stops at the first non-significant endpoint.","paramType":"Adjusted Difference","paramValue":"-16.83","statisticalMethod":"Cochran-Mantel-Haenszel"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"12.11","upperLimit":"25.61","value":"18.9"},{"groupId":"OG001","lowerLimit":"27.50","upperLimit":"43.78","value":"35.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"135"},{"groupId":"OG001","value":"136"}],"units":"Participants"}],"description":"Percentage of participants with death or renal-related events were defined as participants with one or more of the following events: Death; Treatment failure; Worsening proteinuria, defined as a confirmed ≥50% increase in UPCR to a value ≥3 g/g; Worsening eGFR, defined as a confirmed ≥30% decrease in eGFR to a value \\<60. Early study withdrawal due to lack of efficacy was an intercurrent event. Participants experiencing the intercurrent event were considered as participants with events under composite strategy. Analysis was performed using CMH test adjusting for the stratification factors region and race. Missing data was imputed by multiple imputations using FCS predicted mean matching method. Percentages have been rounded off.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received obinutuzumab, 1000 mg as an IV infusion on Day 1 and Weeks 2, 24, 26, and either Weeks 50 and 52 or Week 52 only, along with MMF and SOC therapy. Placebo was administered at Week 50 for participants not treated with obinutuzumab. Participants with adequate response at Week 76 continued to receive obinutuzumab at Week 80 and Q6M thereafter. The dose of MMF can be adjusted at the investigator's discretion beginning at Week 80.","id":"OG000","title":"Obinutuzumab"},{"description":"Participants received Obinutuzumab matching placebo as an IV infusion on Day 1 and Weeks 2, 24, 26, 50, and 52. Participants also received SOC therapy and MMF. Participants with adequate response at Week 76 continued to receive placebo at Week 80 and Q6M thereafter.","id":"OG001","title":"Placebo"}],"paramType":"NUMBER","populationDescription":"Efficacy population included all randomized participants regardless of whether they received study drug. As pre-specified in the SAP, all the endpoints were to be compared between the obinutuzumab (combined treatment groups) and placebo groups.","reportingStatus":"POSTED","timeFrame":"From Day 1 to Week 76","title":"Percentage of Participants Who Experience Death or Renal-related Events","type":"SECONDARY","unitOfMeasure":"percentage of participants"}